CompletedNot Applicable

Second Trimester Maternal Serum Homocysteine Levels and Uterine Artery Doppler for Prediction of Preeclampsia and Placentation Disorders

500 participantsStarted 2015-09

Plain-language summary

The current study included the singleton pregnancies (without history of previous risk factors), had their homocysteine measured as part of a serum-screening program in addition to uterine artery Doppler. Sensitivity, specificity, positive and negative predictive values, for development of preeclampsia and other adverse pregnancy outcomes were assessed as follows; (1) Homocysteine cutoff level at 6.3 µmol/l; (2) Bilateral notches on Doppler with a mean RI \>0.5, all unilateral notches with a mean RI \>0.6, in addition, absence of notches with a mean RI \>0.7; (3) Doppler assessment combined with the homocysteine cutoff (6.3 µmol/l).

Who can participate

Age range18 Years – 39 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Spontaneous pregnancies without history of previous risk factors for preeclampsia Exclusion Criteria: * multiple pregnancy, non-intact renal function, and hypertension before 20 weeks of gestation, diabetes mellitus and/or chronic diseases, women taking folic acid supplementations, women using antifolate drugs, and maternal age more than 40 years

What they're measuring

development of placentation disorders

Timeframe: 28-40 weeks gestational age

Trial details

NCT IDNCT02854501

SponsorCairo University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2016-08

View on ClinicalTrials.gov More Preeclampsia trials